The role of pharmacogenetics in the treatment of major depressive disorder : a critical review
Copyright © 2023 Barlati, Minelli, Nibbio, Bertoni, Necchini, Paolini, Muscarella, Bosco Ubertino, Calzavara-Pinton, Vita and Gennarelli..
Pharmacological therapy represents one of the essential approaches to treatment of Major Depressive Disorder (MDD). However, currently available antidepressant medications show high rates of first-level treatment non-response, and several attempts are often required to find an effective molecule for a specific patient in clinical practice. In this context, pharmacogenetic analyses could represent a valuable tool to identify appropriate pharmacological treatment quickly and more effectively. However, the usefulness and the practical effectiveness of pharmacogenetic testing currently remains an object of scientific debate. The present narrative and critical review focuses on exploring the available evidence supporting the usefulness of pharmacogenetic testing for the treatment of MDD in clinical practice, highlighting both the points of strength and the limitations of the available studies and of currently used tests. Future research directions and suggestions to improve the quality of available evidence, as well as consideration on the potential use of pharmacogenetic tests in everyday clinical practice are also presented.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in psychiatry - 14(2023) vom: 22., Seite 1307473 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barlati, Stefano [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antidepressant |
|---|
| Anmerkungen: |
Date Revised 01.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fpsyt.2023.1307473 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365165719 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365165719 | ||
| 003 | DE-627 | ||
| 005 | 20231226101106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fpsyt.2023.1307473 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365165719 | ||
| 035 | |a (NLM)38025425 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barlati, Stefano |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of pharmacogenetics in the treatment of major depressive disorder |b a critical review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Barlati, Minelli, Nibbio, Bertoni, Necchini, Paolini, Muscarella, Bosco Ubertino, Calzavara-Pinton, Vita and Gennarelli. | ||
| 520 | |a Pharmacological therapy represents one of the essential approaches to treatment of Major Depressive Disorder (MDD). However, currently available antidepressant medications show high rates of first-level treatment non-response, and several attempts are often required to find an effective molecule for a specific patient in clinical practice. In this context, pharmacogenetic analyses could represent a valuable tool to identify appropriate pharmacological treatment quickly and more effectively. However, the usefulness and the practical effectiveness of pharmacogenetic testing currently remains an object of scientific debate. The present narrative and critical review focuses on exploring the available evidence supporting the usefulness of pharmacogenetic testing for the treatment of MDD in clinical practice, highlighting both the points of strength and the limitations of the available studies and of currently used tests. Future research directions and suggestions to improve the quality of available evidence, as well as consideration on the potential use of pharmacogenetic tests in everyday clinical practice are also presented | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antidepressant | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a major depressive disorder | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a pharmacogenetic | |
| 650 | 4 | |a remission | |
| 650 | 4 | |a response | |
| 650 | 4 | |a tolerability | |
| 700 | 1 | |a Minelli, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Nibbio, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoni, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Necchini, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Paolini, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Muscarella, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Ubertino, Ughetta Bosco |e verfasserin |4 aut | |
| 700 | 1 | |a Calzavara-Pinton, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Vita, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Gennarelli, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in psychiatry |d 2010 |g 14(2023) vom: 22., Seite 1307473 |w (DE-627)NLM205737781 |x 1664-0640 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:22 |g pages:1307473 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fpsyt.2023.1307473 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 22 |h 1307473 | ||